Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
NCT ID: NCT00061672
Last Updated: 2007-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
67 participants
INTERVENTIONAL
2003-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-510 - Thrombospondin-1 Mimetic
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject is at least 18 years of age.
* The subject has histologically confirmed non-Hodgkin's Lymphoma (NHL) (excluding Burkitt's, Burkitt's type or HIV associated lymphoma) or Hodgkin's Lymphoma (HL) that is refractory to or has relapsed after standard therapy or for which there is no known effective treatment.
* The subject must have measurable disease by the CHESON Criteria for Tumor Response.
* The subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2.
* The subject is able to self-administer or has a caregiver who can reliably administer subcutaneous injections.
* The subject must have adequate bone marrow, renal and hepatic function as follows:
* Bone marrow: \*White blood cell count (WBC) greater than or equal to 3,000/mm3; \*Platelets greater than or equal to 75,000/mm3 unless subject has received a prior transplant or bone marrow involvement with lymphoma has been documented, then platelets of equal to or greater than 50,000 is acceptable. \*Hemoglobin greater than or equal to 8.5 g/dL; \*ANC greater than or equal to 1000/mm3
* Renal function: \*Serum creatinine less than or equal to 2.0 mg/dL
* Hepatic function: \*AST and ALT less than or equal to 3.0 X ULN
* The subject must not be pregnant or lactating and all subjects (male and female) must use a contraceptive method deemed appropriate by the investigator while in the study and up to two months following completion of therapy.
* The subject has voluntarily signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent prior to any study specific procedures.
Exclusion Criteria
* The subject has a history of or currently exhibits Central Nervous System (CNS) metastasis. Brain MRI within 28 days of enrollment is required to confirm absence of CNS metastases.
* The subject is receiving therapeutic anticoagulation therapy. Low dose anticoagulation (e.g., low dose Coumadin) for catheter prophylaxis is permitted; PT/PTT must be within normal limits.
* The subject has a history of or currently exhibits clinically significant cancer related events of bleeding (e.g., hemoptysis). The subject has a recent history of (within 4 weeks of Study Day 1) or currently exhibits other clinically significant events of bleeding.
* The subject has received any therapy for lymphoma including chemotherapy, antibody therapy, radiotherapy or any investigational therapy within four weeks prior to study drug administration.
* The subject has been initiated on steroids or there is an increase in current steroid dose within three months prior to study drug administration.
* The subject exhibits evidence of clinically significant uncontrolled condition(s) and/or is considered by the investigator to be unable to tolerate the proposed treatment or procedures.
* The subject has history of other previous malignancies within 5 years, with the exception of: Adequately treated in situ carcinoma of the cervix; Basal or squamous cell carcinoma of the skin.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rod Humerickhouse, MD
Role: STUDY_DIRECTOR
Abbott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hematology Oncology Associates
Phoenix, Arizona, United States
Arizona Clinical Research Center
Tucson, Arizona, United States
USC - Norris Cancer Center
Los Angeles, California, United States
The Center for Hematology-Oncology
Boca Raton, Florida, United States
Oncology-Hematology Group of South Florida
Miami, Florida, United States
Cancer Centers of Florida, P.A.
Orlando, Florida, United States
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States
Arch Medical Services, INC.
St Louis, Missouri, United States
Albany Regional Cancer Center
Albany, New York, United States
Raleigh Hematology Oncology Clinic
Cary, North Carolina, United States
The West Cancer Clinic
Memphis, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
Hematology Oncology Associates
San Antonio, Texas, United States
U of W - Comprehensive Care Center
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M02-457
Identifier Type: -
Identifier Source: org_study_id